In order to identify anaplastic lymphoma kinase-driven non-small cell lung cancer (ALK 1 NSCLC) patients with a worse outcome, who might require alternative therapeutic approaches, we retrospectively analyzed all stage IV cases treated at our institutions with one of the main echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion variants V1, V2 and V3 as detected by next-generation sequencing or reverse transcription-polymerase chain reaction (n 5 67). Progression under tyrosine kinase inhibitor (TKI) treatment was evaluated both according to Response Evaluation Criteria in Solid Tumors (RECIST) and by the need to change systemic therapy. EML4-ALK fusion variants V1, V2 and V3 were found in 39%, 10% and 51% of cases, respectively. Patients with V3-driven tumors had more metastatic sites at diagnosis than cases with the V1 and V2 variants (mean 3.3 vs. 1.9 and 1.6, p 5 0.005), which suggests increased disease aggressiveness. Furthermore, V3-positive status was associated with 
Introduction
Anaplastic lymphoma kinase (ALK) fusion genes are the driver genetic alteration in approximately 5% of non-small cell lung cancers (ALK 1 NSCLC). 1 In >90% of cases, these occur when inversions in chromosome 2 juxtapose a varying 5 0 -end part of the echinoderm microtubule-associated protein-like 4 (EML4) gene with the entire tyrosine kinase domain (exons 20-29) of ALK, which then undergoes aberrant expression and constitutive activation due to the EML4 promoter and oligomerization domains. 2 Ever since this insight 10 years ago, ALK-specific tyrosine kinase inhibitors (TKI) are being developed and have consistently shown superior efficacy and tolerability compared to first and second-line chemotherapy. 3 Crizotinib, ceritinib, alectinib and brigatinib (in the US) are already approved for routine patient care, while the third-generation compound lorlatinib currently undergoes advanced clinical testing. For most patients with disease progression under these targeted treatments, after 1 to 2 years on average depending on the compound used, a second and even a third disease remission of several months' duration is still possible by treatment with a different TKI, ideally based on the results of conventional or liquid tumor biopsy. 4 On the other hand, for patients with ongoing clinical benefit and disease progression restricted to specific sites ("oligoprogression"), either intra-or extracranial, continuation of the same TKI and local ablative therapies also prolong survival. [5] [6] [7] Thus, owing to TKI sequencing combined with local treatments, patients with metastatic ALK 1 NSCLC nowadays have the most complex management and experience the longest survival among all stage IV NSCLC patients, currently exceeding 5 years in median after two ALK inhibitors. 8 This represents a new situation for thoracic oncology, in which median overall survival (OS) intervals with chemotherapy-based treatment of metastatic disease have always lain below one-and-ahalf years, 9 and poses a special challenge: the identification within the now generally favorable ALK 1 NSCLC patient group of cases with higher risk, which should preferentially be offered access to experimental treatments and more aggressive surveillance strategies, similar to the practice regarding other relatively favorable tumor entities, like various B-cell malignancies.
Based on the variability of EML4-ALK fusion genes among different patients 10 and their dominant role in the biology of ALK 1 NSCLC, some studies have explored a potential association between the EML4-ALK fusion variant and response to treatment, but the results have been inconclusive. Lei et al. did not detect any significant difference in the efficacy of crizotinib between patients with the EML4-ALK fusion variant V3 (coexisting V3a/b splice variants containing EML4 exons 1-6 and present in about 1/3 cases), V1 (containing EML4 exons 1-13, also in about 1/3 of cases) and other, less frequent variants (V2 being the most common, with EML4 exons 1-20 and present in about 10% of cases). 11 In contrast, Yoshida et al. and Cha et al. reported a better progression-free survival (PFS) of patients with V1 after treatment with crizotinib and pemetrexed, respectively, but the comparator in both studies was heterogeneous with many different variants pooled together. 12, 13 More recently, Woo et al. described a shorter PFS after treatment with various ALK inhibitors for patients with V3 after dichotomizing the different EML4-ALK fusion variants according to the expected stability of the resulting oncoprotein.
14 However, the clinical relevance of this study was questioned due to the lack of a difference in OS, 15 and because PFS was defined using the Response Evaluation Criteria in Solid Tumors (RECIST) 16 without accounting for the usual practice of TKI continuation beyond disease progression (CBDP), which prolongs survival. 5 Here, we address this problem by studying larger, homogeneous groups of ALK 1 NSCLC patients with detailed clinical annotation and a longer follow-up. Initially, we explore how each of the main ALK fusion variants V1, V2 and V3 affects the metastatic spread of the disease before the beginning of treatment, which is an indicator of biological aggressiveness independent of the applied therapy. Subsequently, we examine the influence of the ALK fusion variant on response to the common therapeutic What's new? EML4-ALK fusions are driving 5% of non-small cell lung cancers (NSCLC). The present study shows for the first time that a specific fusion variant, namely V3 (E6;A20), is associated with more aggressive disease and worse overall survival due to earlier failure of several therapeutic modalities. This will necessitate inclusion of molecular assays beyond FISH in future diagnostic guidelines for ALK 1 NSCLC and prompt development of more efficient strategies for the management of higher-risk, V3-positive cases.
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Patients and Methods
Included in this retrospective analysis were all 67 ALK 1 patients with metastatic lung adenocarcinoma treated at the Thoraxklinik Heidelberg and Lungenklinik L€ owenstein, for which analysis of the ALK fusion was feasible and showed one of the common EML4-ALK variants V1, V2 and V3 (Fig. 1) . Clinical data were collected through a review of patient records and radiological images with a chest CT and brain MRI-based restaging of 6-12 weeks. To reflect current standard practice of TKI CBDP in ALK 1 NSCLC, the time to treatment failure of TKI treated patients was evaluated with two alternative methods: (i) by defining progression according to RECIST v1.1 16 (PFS) and (ii) according to the need for switch of systemic therapy as judged by the treating physicians on grounds of clinical benefit (time to next treatment [TNT]). 5, 15 Brain PFS was defined as the time to either radiologic progression in brain MRI according to RECIST v1.1 or death. Our study was approved by the Ethics committee of the Heidelberg University (S-296/2016).
Diagnosis of lung adenocarcinoma and detection of EML4-ALK fusion variants by next-generation sequencing
The histological diagnosis of lung adenocarcinoma and the quantification of tumor cell content were performed by experienced pulmonary pathologists on formalin-fixed and paraffin-embedded (FFPE) small biopsies according to the WHO and IASLC/ATS/ ERS criteria. 17 Newly diagnosed cases were screened for the For the NGS detection of ALK fusions, areas with at least 15% tumor cellularity were marked on a hematoxylin/eosinstained slide and macrodissected manually from subsequent 8 lm thick specimen sections, followed by sample deparaffinization and digestion with Proteinase K overnight. Nucleic acids were then extracted with the automated system Promega Maxwell 16 LEV RNA FFPE Purification Kit (Promega, Madison, WI), treated with DNaseI at room temperature for 15 min and used for RNA-based library preparation. The RNA concentration was measured fluorimetrically using the QuBit 2.0 RNA high sensitivity kit (ThermoFisher Scientific, Waltham, MA) with a minimum of 1 ng/ml set as quality threshold. For library preparation, the multiplex PCR-based Ion Torrent AmpliSeq technology (ThermoFisher) was used together with the RNA Lung Cancer Fusion Panel as described previously. 18 Only samples achieving library concentrations > 100 pM were considered suitable for further processing. Raw sequencing data were processed using the Torrent Suite Software (version 4.2.1) and aligned against the human genome (version hg19) using the Torrent Mapping Alignment Program algorithm. EML4-ALK fusion transcripts were detected using the fusion workflow integrated in the Ion Reporter Software (versions 4.2 and 5.2) as described previously. 18 
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Detection of the V1 and V3 EML4-ALK fusion variants by RT-PCR
For the RT-PCR based detection of V1 and V3 ALK fusion variants, tumor RNA was reverse transcribed using the SuperScript III One Step RT-PCR System (Invitrogen, ThermoFisher) and amplified with primers specific for the EML4 exons 6 and 13 and the ALK exon 20 (sequences given in the Online Supplements). Direct sequencing of the PCR amplicons was performed for both strands on a 3500 Genetic Analyzer using the BigDye Terminator v1.1 Cycle Sequencing Kit (both from Applied Biosystems, Life Technologies, Carlsbad, CA). Since RT-PCR represented only a temporary solution in our laboratory and was succeeded by NGS in 2015 for the typing of ALK fusion variants, we chose not to invest additional resources in the establishment of RT-PCR assays specific for less frequent variants like V2.
ALK IHC and FISH
For the ALK IHC a sensitive and specific antibody (D5F3 clone, Roche, Mannheim, Germany) 19 was used according to current guidelines. 20 For the correlation of IHC results with other data, IHC slides were evaluated for the percentage of ALK 1 cells and their staining intensity (graded as 0,1,2,3) by a pathologist blinded to other patient data. ALK FISH analyses were performed on whole block slides of FFPE NSCLC samples using a break-apart probe (ZytoLight SPEC ALK probe, ZytoVision GmbH, Bremerhaven, Germany). At least 100 cells were analyzed per case, and cases were considered to be positive when 15% or more of 50 tumor cells showed classic split signals. 20 
Statistical analysis
Survival data were analyzed according to Kaplan-Meier and compared with the log-rank test. The independent effect of more variables on survival was examined with a Cox regression. Numerical data were compared across three groups using oneway analysis of variance (ANOVA) with the Welch's test and the Games-Howell post hoc test (due to unequal sample sizes and variances), and across two groups by an unpaired t test. Categorical data were compared with the v 2 test. Statistical calculations were performed with GraphPad Prism version 7 (GraphPad Software, La Jolla, CA, USA) and SPSS version 24 (IBM Corp., Armonk, NY).
Results
One of the main EML4-ALK fusion variants V1, V2 and V3 was detected in 67 patients with metastatic NSCLC by either NGS (n 5 43) or RT-PCR (n 5 24, Fig. 1 ). Most prevalent was V3 (51%), followed by V1 (39%) and V2 (10%). The baseline characteristics, treatment and follow-up of patients included in our study are summarized in Table 1 .
Initially, we assessed the metastatic spread among patients with tumors bearing the V1, V2 and V3 fusion variants at initial diagnosis as an indicator of biological aggressiveness and a priori, that is, independent of treatment, clinical risk. ALK 1 NSCLC patients with variant V3 had a higher number of metastatic sites than patients with the non-V3 variants V1 and V2 (mean 3.25 vs. 1.88 and 1.57), which appeared similar in this regard and were therefore grouped together for further analyses (Fig. 2) . Both lung and extrathoracic metastases were more frequent in V3 cases, including a higher rate of lesions in atypical locations, like the spleen, kidneys, skin and extrathoracic lymph nodes (Table 1) .
Patients with V3-driven NSCLC had a shorter PFS as analyzed by RECIST after treatment with first or second-generation ALK TKI in the first and second line (7.3 vs. 39.3 months and 5.0 vs. 11.3 months, respectively, Figs. 3a and 3b) as well as after first-line treatment with platinum-based combination chemotherapy (5.4 vs. 15.2 months in median, Fig. 4a ). For TKI-treated patients, the alternative analysis of TNT considering CBDP improved the curves of both V3 and V1/2 groups and reduced the difference between them (Figs.  3c and 3d ), but the disadvantage of V3 patients under TKI treatment remained significant when the first and second treatment lines were considered together (p 5 0.019, Fig. 3f ). When patients treated with chemotherapy and TKI in the first line were grouped together, the fusion variant (V1/2 vs. V3) was more important than the type of first-line treatment (TKI vs. chemotherapy) for a longer time until beginning of the second treatment line (HR 0.342, p 5 0.007 vs. HR 0.407, 
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p 5 0.031, respectively, in a bivariable Cox regression). In the subgroup of patients with cerebral radiotherapy during firstline treatment (n 5 13), presence of the V3 variant was predictive of a shorter brain PFS (6.1 months vs. not reached, Fig. 4b ). In the entire cohort (n 5 67), V3 patients had a shorter OS, regardless of whether this was calculated from the diagnosis of metastatic disease (39.8 vs. 59.6 months, Fig. 5 ) or from initial diagnosis (39.8 vs. 61.8 months, suppl. Fig. 1 ).
Due to its prominent predictive and prognostic significance, we examined whether the presence of the EML4-ALK fusion variant V3 was associated with any morphological tumor characteristics. No significant differences could be detected in the biopsies of V3 vs. V1/2 tumors regarding the growth pattern of adenocarcinoma (acinar and/or solid in most cases), the presence of signet-ring cells and/or mucinous features, 21 and the percentage of positive cells or their staining intensity in ALK IHC (Table 1 ).
Discussion
Life expectancy of patients with metastatic ALK 1 NSCLC has improved considerably during the past years. Through sequential TKI administration combined with local ablative treatments median OS currently exceeds 5 years after two ALK inhibitors. 8 This represents a major therapeutic success, but at the same time underscores the need to identify ALK 1 NSCLC patients with worse outcome, for which alternative management strategies should be pursued. The data presented in our study show that the presence of the EML4-ALK fusion variant V3 is such a high-risk feature. V3 influences the natural history of the disease by conferring an accelerated metastatic spread, is associated with earlier failure of several therapeutic modalities, namely TKI, chemotherapy and cerebral radiotherapy, and ultimately results in shorter OS.
In our study, the relatively large, homogeneous, balanced groups of NSCLC patients with each of the main fusion variants V1, V2 and V3, the detailed clinical annotation and the longer patient follow-up of 29 months in median allowed to demonstrate these significant effects. In a previous study with fewer patients, a trend for lower response rate of V3 cases to crizotinib did not reach statistical significance, 11 while two 4 All cases received bevacizumab, except for one V1/2 case that received cetuximab. 5 Systemic first-line therapy was crizotinib, except for one V1/2 case that received ceritinib and one V1/2 case that received platinum/pemetrexed. Most patients were irradiated as part of initial treatment for metastatic disease, while three patients (one V1, two V3) received radiotherapy as part of a CBDP strategy. Radiation dose was 30 Gy in 10 fractions, while one case (V3) additionally received 9 Gy in 3 fractions as sequential boost of a metastasis in the left frontal lobe. 6 All patients were irradiated as part of initial treatment for metastatic disease and received as systemic first-line therapy crizotinib; two patients received 30 Gy in 5 fractions (one V3 and one V1), one patient a single fraction of 18 Gy at the 70% isodose (V3) and one patient a single fraction of 20 Gy at the 50% isodose for one 1 cm large supratentorial metastasis as well as for nine other 2-4 mm large lesions discovered during the radiotherapy planning brain MRI (V3). 7 Excluding video-assisted thoracoscopy with pleurodesis for pleural effusion. 8 Nodules and/or effusion. 9 Spleen, kidneys, skin, cervical and retroperitoneal lymph nodes. Abbreviations: IQR: interquartile range; ns: not statistically significant; py: pack-years; SD: standard deviation; CBDP: treatment continuation beyond disease progression. Table 1 .
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other reports observed a better efficacy of TKI or pemetrexed chemotherapy for V1 patients, but as comparator they pooled together patients with several different variants. 12, 13 More recently, Woo et al. described a shorter PFS after treatment with various ALK inihbitors for patients with V3 after dichotomizing the different EML4-ALK fusion variants according to the expected stability of the resulting oncoprotein.
14 However, the clinical relevance of this finding was questioned, primarily due to the lack of a difference in OS, which the authors ascribed to the low number of events at a median follow-up of 15 months as well as to treatment imbalances between the two groups. 14, 15 In addition, this study was criticized because the observed PFS difference was based on a definition of progression by RECIST without accounting for the current practice of CBDP, which prolongs survival. 5, 15 The clinical relevance of the V3 vs. non-V3 distinction in our study is underlined by its impact on OS (Fig. 5) and by its influence on the natural history of the disease per se: stage IV V3 cases had a higher number of total and atypical metastatic sites at initial diagnosis than stage IV V1 and V2 cases, which is an indicator for disease aggressiveness before and independent of any therapeutic intervention ( Fig. 2 ; Table 1 ). In line with this, the shorter PFS for V3 cases in our study did not pertain only to treatment with TKI (Fig. 3) , but was also observed after chemotherapy and after cerebral radiotherapy (Fig. 4) . Thus, V3-positive status qualifies as a global high-risk factor for ALK 1 NSCLC independent of the treatment applied. Notably, this holds true regardless of whether progression is defined according to RECIST or by additionally taking CBDP into account (Fig. 3) . A biochemical explanation for a potentially greater oncogenic impact of V3 was elaborated by Richards et al.: oncoproteins of the V1 and V2 EML4-ALK fusion variants have disrupted b-propeller folding, which causes instability and earlier degradation, whereas oncoproteins of the V3 variant completely lack the propeller domains and are therefore more stable. 22 Nevertheless, other, still poorly understood biochemical parameters could additionally influence the effect of individual fusion variants on patient outcome. For example, even though V1 and V2 oncoproteins are both predicted to be unstable due to misfolded, partial propeller domains and show a similar sensitivity to HSP90 inhibition in vitro, 22, 23 V2 has a shorter half-life and a lower IC50 to crizotinib than V1, 23 and some data suggest that V2 patients might indeed have an even better clinical course than V1 cases. 24 These considerations additionally support our Table 1 . Firstline chemotherapy treatment was platinum-based for all patients. grouping of V2 together with V1 and separately from the higher-risk V3.
The more intense oncogenic signaling of V3 compared to V1 and V2 carrying cells, evident in vitro as increased ALK phosphorylation and a higher IC50 to various ALK TKI, 14 has several important implications for the biology of V3-driven tumors. The increased number of total and atypical metastatic sites among stage IV ALK 1 NSCLC patients with V3 tumors observed in our study (Fig. 2) could reflect an even more pronounced "oncogene-biology," analogous to the generally increased incidence of intra-and extrathoracic metastases of ALK 1 and EGFR 1 tumors compared to wild-type NSCLC. 25 In the same line, a higher percentage of metastatic disease for V3 patients compared to V1, V2 and other, less frequent variants was reported very recently by another study, which considered stage I-III (87%) and IV (13%) ALK 1 NSCLC cases together. 26 Furthermore, this "oncogene-biology" also entails a relative resistance to immune checkpoint inhibitor therapy, 27 which suggests that immunotherapy may also be less effective in patients with V3-driven ALK 1 tumors. Finally, the higher oncogenic drive associated with V3-positive status appears to promote development of more secondary ALK TKI resistance mutations, 28 which are rare at baseline 29 and represent another important mechanism of ALK TKI failure in these patients besides the higher IC50 of "wild-type" V3. 14 No morphologic parameter could be identified that correlated with the presence of V3 in tumor biopsies of ALK 1 NSCLC patients. Thus, detection of V3 and other ALK fusion variants presently necessitates molecular testing by NGS or RT-PCR. These methods, however, are not part of the current diagnostic guidelines, which prioritize ALK IHC and FISH. 30 The predictive and prognostic value of the V3 variant in our study argues for a V3 assay as part of the initial workup for ALK 1 NSCLC. This could most easily be implemented by a complementary RT-PCR assay, while an NGS approach would also facilitate simultaneous detection of other therapeutically relevant translocations as well as enhance sensitivity and specificity in the determination of ALK 1 status. 18, 31, 32 Upfront NGS testing in particular is a time-efficient and material-sparing strategy for parallel detection of actionable genetic alterations in NSCLC with failure rates of approximately 10%, 18 which is considerably lower than the 32%-50% drop-out rate in the detection of ALK fusion variants observed in the current and other studies after serial application of different methods on the limited material obtained from small biopsies.
11-14
The shorter duration of response observed for V3 patients under all main therapeutic modalities, namely TKI, chemotherapy and radiotherapy, and the inferior survival suggest a need for alternative management strategies. The very recent approval of alectinib for first-line treatment of ALK 1 NSCLC is probably not going to solve the problem, because in vitro data show a similar resistance of V3 expressing cells to alectinib, crizotinib and ceritinib with IC50 values >500 nM. 14 Whether upfront treatment with newer ALK TKI could negate the V3-associated risk, is unclear at present. Other strategies to consider currently are a more intense monitoring of V3 ALK 1 patients with radiologic studies and ctDNA assays as well as a more aggressive approach regarding local ablative treatments. We anticipate the development of novel management strategies and drugs against the high-risk, V3-driven disease to become a main research objective in ALK 1 NSCLC. In summary, our study shows that the EML4-ALK fusion variant V3, present in one-third to one-half of patients in this and other series, is a high-risk feature in ALK 1 NSCLC conferring early metastatic spread, treatment failure after TKI, chemotherapy and cerebral radiotherapy and inferior OS. These data strongly suggest the adoption of V3 status for risk stratification in ALK 1 NSCLC, which will affect diagnostic algorithms and influence future therapeutic strategies.
